Upcoming Webinars
December 4, 2025, 3 PM ET
The CHALLENGE Trial was Positive: What's Next for the Field of Exercise Oncology?
In this presentation, Prof. Courneya will present the results of the groundbreaking CHALLENGE trial demonstrating that structured exercise after adjuvant chemotherapy for colon cancer improves survival. He will then discuss the implications of the first positive phase 3 exercise trial on clinical practice and future research.
February 26, 2026, 3 PM ET
Improving Oncology Outcomes Through Targeted Nutritional Assessment and Intervention
Cancer and its treatments substantially impact nutritional status and overall patient outcomes. Malnutrition and muscle loss are highly prevalent challenges that compromise treatment tolerance, increase toxicity, and diminish quality of life and survival. This presentation will highlight emerging evidence on the role of targeted nutrition strategies, emphasizing the importance of comprehensive assessment and individualized intervention. Drawing on data from clinical trials and translational research, the session will explore updated insights into energy and protein requirements in oncology, including how factors such as inflammation influence anabolic response. It will also underscore the importance of integrating nutrition into multidisciplinary cancer care to optimize outcomes across the continuum.
April 9, 2026, 2 PM ET
Coffee consumption and improved colorectal cancer survivorship: from observational to interventional studies
Observational findings from several independent cohorts have consistently shown a beneficial association of coffee consumption after diagnosis with better survival outcomes among patients with colorectal cancer. In support of these data, coffee has been linked to lower risk of metabolic disorders, lower inflammation, and favorable blood biochemical profiles. While the components in coffee that drive these benefits remain unknown, studies of metabolomics and microbiome have identified potential molecules and mechanisms of action underlying coffee's beneficial effects. These data altogether have motivated the conduct of the first randomized control trial of coffee consumption among colorectal cancer survivors (the COMMENCER trial). In this presentation, Dr. Song will review the existing data, present the COMMENCER trial, and discuss the future directions.
Past Webinars
The recording of this webinar session will be made available after the presenters publish their research findings.